Yihua Liu1, Yefan Jiang1, Xiaoxi Yang2, Bingchuan Geng1, Yi Liu1, Xiaoke Shang1, Jinping Liu1, Xiaoli Lan3, Nianguo Dong1. 1. Department of Cardiovascular Surgery and Heart Transplantation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2. Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China. 3. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Abstract
BACKGROUND: Myocardial viability assessment is typically performed in patients with coronary artery disease (CAD) and severe left ventricular (LV) dysfunction to identify those who might benefit from revascularization and assist in decision making process. However, the prognostic value of myocardial viability testing remains a debating issue. METHODS: Positron Emission Tomography using 18F-fluorodeoxyglucose (18FDG-PET) was performed in 81 patients with ischemic LV dysfunction [ejection fraction (EF) ≤35%] for myocardial viability assessment prior to coronary artery bypass surgery. Fifty-three of them received finally coronary artery bypass grafting and were divided into two groups according to the extent of myocardial scar: one group with scar burden ≥10% (n=30) and the other with scar burden <10% (n=23). The remaining patients were contraindicated for CABG and received optimal medical treatment (OMT, n=28). All patients were followed up and the primary endpoint was all-cause mortality and the secondary endpoint was a composite of all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE). RESULTS: 18FDG-PET revealed a different profile of myocardial viability among three groups with respect to the extent of myocardial scar, the hibernating myocardium (both P<0.01), some echocardiographic parameters such as left ventricular diastolic dimension (LVDD) and EF were also significantly different (both P<0.05). Nevertheless, the baseline prevalence of comorbidities and functional classifications were comparable. The per-procedural parameters were not significantly different between two CABG groups. In a median follow-up time of 32 months, Kaplan Meier analysis uncovered no significant difference in terms of overall survival (P=0.74) and MACCE-free survival (P=0.66) among three groups. CONCLUSIONS: Myocardial viability assessment using 18FDG-PET is of limited prognostic value in patients with CAD and severe LV dysfunction. In patients with substantial myocardial scar burden despite the existence of considerable hibernating myocardium, functional recovery following surgical revascularization is not necessarily translated to survival benefits.
BACKGROUND: Myocardial viability assessment is typically performed in patients with coronary artery disease (CAD) and severe left ventricular (LV) dysfunction to identify those who might benefit from revascularization and assist in decision making process. However, the prognostic value of myocardial viability testing remains a debating issue. METHODS: Positron Emission Tomography using 18F-fluorodeoxyglucose (18FDG-PET) was performed in 81 patients with ischemic LV dysfunction [ejection fraction (EF) ≤35%] for myocardial viability assessment prior to coronary artery bypass surgery. Fifty-three of them received finally coronary artery bypass grafting and were divided into two groups according to the extent of myocardial scar: one group with scar burden ≥10% (n=30) and the other with scar burden <10% (n=23). The remaining patients were contraindicated for CABG and received optimal medical treatment (OMT, n=28). All patients were followed up and the primary endpoint was all-cause mortality and the secondary endpoint was a composite of all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE). RESULTS: 18FDG-PET revealed a different profile of myocardial viability among three groups with respect to the extent of myocardial scar, the hibernating myocardium (both P<0.01), some echocardiographic parameters such as left ventricular diastolic dimension (LVDD) and EF were also significantly different (both P<0.05). Nevertheless, the baseline prevalence of comorbidities and functional classifications were comparable. The per-procedural parameters were not significantly different between two CABG groups. In a median follow-up time of 32 months, Kaplan Meier analysis uncovered no significant difference in terms of overall survival (P=0.74) and MACCE-free survival (P=0.66) among three groups. CONCLUSIONS: Myocardial viability assessment using 18FDG-PET is of limited prognostic value in patients with CAD and severe LV dysfunction. In patients with substantial myocardial scar burden despite the existence of considerable hibernating myocardium, functional recovery following surgical revascularization is not necessarily translated to survival benefits.
Authors: Brian Mc Ardle; Tushar Shukla; Graham Nichol; Robert A deKemp; Jordan Bernick; Ann Guo; Siok Ping Lim; Ross A Davies; Haissam Haddad; Lloyd Duchesne; Paul Hendry; Roy Masters; Heather Ross; Michael Freeman; Karen Gulenchyn; Normand Racine; Dennis Humen; Francois Benard; Terrence D Ruddy; Benjamin J Chow; Lisa Mielniczuk; Jean N DaSilva; Linda Garrard; George A Wells; Rob S B Beanlands Journal: Circ Cardiovasc Imaging Date: 2016-09 Impact factor: 7.792
Authors: Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Rob S B Beanlands; Graham Nichol; Ella Huszti; Dennis Humen; Normand Racine; Michael Freeman; Karen Y Gulenchyn; Linda Garrard; Robert deKemp; Ann Guo; Terrence D Ruddy; Francois Benard; André Lamy; Robert M Iwanochko Journal: J Am Coll Cardiol Date: 2007-10-10 Impact factor: 24.094
Authors: Rob S B Beanlands; Terrence D Ruddy; Robert A deKemp; Robert M Iwanochko; Geoffrey Coates; Michael Freeman; Claude Nahmias; Paul Hendry; Robert J Burns; Andre Lamy; Lynda Mickleborough; William Kostuk; Ernest Fallen; Graham Nichol Journal: J Am Coll Cardiol Date: 2002-11-20 Impact factor: 24.094